drugset / Trial / NCT03097627

Intravenous Indocyanine Green for Localization of Intra-thoracic Lesions

NCT03097627

Phase 1/2 Completed 4 enrolled Brigham and Women's Hospital
NaSingle-groupOpen-labelDevice feasibility

Summary

This is a clinical trial to evaluate the intravenous administration of indocyanine green (ICG) as a method of intra-thoracic lesion localization. The primary purpose is to determine if intravenous ICG allows us to identify intra-thoracic lesions.

Timeline

Start
2016-02-01
Primary completion
2016-10-28
Completion
2016-10-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Indocyanine Green Diagnostic / imaging agent 0.5 mg/kg Intravenous

Indications